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The nuclear immunoreactivity for thyroid transcription factor-1 (TTF-1) is a useful marker for identification of carcinomas of thyroid and lung origin. Our aim was to determine whether cytoplasmic staining in the liver is a result of cross-reaction of anti-TTF-1 antibody (clone 8G7G3
Thyroid transcription factor-1 (TTF-1), a homeodomain containing DNA-binding protein, was first described in rat thyroid follicular cells as a regulator of thyroid-specific genes. [1] [2] [3] Subsequently, it was identified in lung (type II cells and Clara cells) and ventral forebrain. 4, 5 TTF-1 is a member of the NKx2 family of homeodomain transcription factors and is also called NKx2.1 and TITF1.
Human TTF-1 (locus, NC_000014) is a single polypeptide 371 amino acids long ❚Figure 1❚; the gene has been mapped to chromosome 14q13. This gene contains 2 exons that produce an approximately 2.4-kb messenger RNA (mRNA) transcript coding for an approximately 41-kd protein. The mouse TTF-1 gene contains 3 exons producing 2 isoforms; the predominant transcript includes exon 2 and exon 3 coding for a 371-amino acid protein, whereas a minor transcript includes all 3 exons that encode a 401-amino acid isoform of TTF-1. 6, 7 TTF-1 is a useful immunohistochemical marker for carcinomas of thyroid and lung origin. [8] [9] [10] [11] Normal hepatocytes and hepatocellular carcinoma often display cytoplasmic TTF-1 immunoreactivity (mainly from clone 8G7G3/1, DAKO, Carpinteria, CA). This immunoreactivity has been used in the differential diagnosis of primary and metastatic carcinomas of the liver. 12,13 TTF-1 cytoplasmic staining (clone 8G7G3/1), together with cytokeratin 19, might also serve as a useful marker for the differential diagnosis of hepatocellular carcinoma from cholangiocarcinoma. 14 Our aim was to determine whether this cytoplasmic staining is a result of a cross-reaction with anti-TTF-1 antibody (clone 8G7G3/1) or true positivity resulting from aberrant expression of TTF-1 or products of alternative splicing of the TTF-1 gene.
Materials and Methods
We obtained 6 cases with fresh tissue samples, 3 explanted livers (2 for cirrhosis and 1 for acute rejection), 1 liver from a lobectomy for metastatic colon adenocarcinoma, 1 thyroid (goiter), and 1 lung from a lobectomy for adenocarcinoma. Studies included immunohistochemical staining, RNA extraction and reverse transcriptase-polymerase chain reaction (RT-PCR), and protein extraction and Western blot.
Immunohistochemical Stains
Immunohistochemical stains were performed from formalin-fixed, paraffin-embedded tissue sections using a commercially available primary antibody (monoclonal mouse anti-TTF-1, clone 8G7G3/1) and a detection kit (DAKO) per the manufacturer's protocol. Briefly, 4-µm-thick sections were deparaffinized, quenched with 3% hydrogen peroxide for 6 minutes, and heated for 40 minutes at 95°C to 99°C in an antigen retrieval solution in a steamer. The slides were stained for 60 minutes with primary antibodies (1:200 dilution) followed by a detection process (horseradish peroxidase-liquid DAB+ System, DAKO).
RNA Extraction and RT-PCR
Total RNA was isolated from freshly obtained surgical specimens using TRIzol reagent (Invitrogen Life Technologies, Grand Island, NY). Briefly, 100 mg of tissue was pulverized under liquid nitrogen; 1 mL of TRIzol reagent was added, and the lysate was further homogenized for about 5 minutes. Phase separation and RNA purification were then performed. Next, 2 µg of total RNA was primed with random hexamers and reverse transcribed into complementary DNA (cDNA) per standard protocol. Only 1 µL of the diluted cDNA mixture was used for the subsequent PCR analysis. 15 The TTF-1 mRNA level was measured by RT-PCR using 3 pairs of primers ( Figure 1 ). Also, a pair of primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA, a housekeeping gene, was used as an internal control for verifying the quality and quantity of mRNA. The PCR primers for the TTF-1 and GAPDH genes were designed using Oligo v4.1 software (Molecular Biology Insights, Cascade, CO).
All PCR primer sequences used in the study for TTF-1 cDNA and GADPH cDNA were as follows: P1 sense primer, 5'-ATG TCG ATG AGT CCA AAG CAC-3'; P2 antisense primer, 5'-CGC TGT TCC TCA TGG TGT CC-3'; P3 sense primer, 5'-CGC TTC CCC GCC ATC TCC-3'; P4 antisense primer, 5'-GGC CTG GCG CTT CAT TTT GTA G-3'; P5 sense primer, 5'-CGA GCG GCA TGA ACA TGA G-3'; P6 antisense primer, 5'-CTT GGC CTG GCG CTT CAT T-3'; GAPDH sense primer, 5'-TGA AGG TCG GAG TCA ACG GAT TTG GT-3'; and GAPDH antisense primer, 5'-CAT GTG GGC CAT GAG GTC CAC CAC-3'.
PCR was initiated by adding 1 µL of the diluted cDNA into a 19-µL master PCR reaction mixture per standard protocol by using an annealing temperature of 63°C for all primers. To keep the PCR in exponential phase, RT-PCR for GAPDH mRNA was conducted for only 25 cycles. RT-PCR for TTF-1 mRNA was performed for 28 to 35 cycles.
Protein Extraction and Western Blot
Surgical specimens were pulverized and homogenized in cold radioimmunoprecipitation assay buffer per standard protocol. The tissue lysates were centrifuged at 16,000g for 30 minutes at 4°C. The total protein concentration was determined, and 20 µg of total protein was analyzed onto an 8% polyacrylamide gel. Precision Plus Protein Standards were from Bio-Rad, Hercules, CA. The proteins from the gels were electrotransferred onto a polyvinylidene fluoride membrane (Bio-Rad) using a semidry electrotransfer system (Bio-Rad). The membrane was then incubated with primary antibody against β-actin (Sigma A5316, dilution 1:5,000; Sigma, St Louis, MO) or primary antibody against TTF-1 (clone 8G7G3/1, dilution 1:500) for 3 hours at room temperature. Afterward, the membranes were incubated with 
Results
Strong and diffuse cytoplasmic immunoreactivity for TTF-1 (clone 8G7G3/1) was detected in hepatocytes of cirrhotic liver ❚Image 1B❚ and ❚Image 1D❚ and noncirrhotic liver resected for metastatic adenocarcinoma of colon ❚Image 1F❚ (nontumor area). Weak cytoplasmic immunoreactivity for TTF-1 was detected in a liver explanted owing to severe rejection ❚Image 1H❚. High magnification (×600) ❚Image 1I❚ revealed diffuse and granular cytoplasmic immunoreactivity for TTF-1 (clone 8G7G3/1) in hepatocytes. Thyroid tissue showed strong nuclear staining as a staining control sample (data not shown). Western blot analysis using the same antibody (clone 8G7G3/1) revealed a very prominent band corresponding to an approximately 160-kd protein from liver tissue but not from thyroid ❚Image 2A❚ or nontumor lung tissue (data not shown) samples. Thyroid tissue contained an approximately 41-kd protein in Western blot (Image 2A). The primary antibody, anti-β-actin, was also used as an internal control in Western blot analysis to verify that the same amount of total protein was loaded in the gel (data not shown).
The mRNA of TTF-1 was not detected in liver tissue samples by RT-PCR in up to 35 cycles using all 3 pairs of primers, whereas the positive control thyroid tissue sample yielded a 300-base-pair (bp) product using primers P3 and P4, a 269-bp product using primers P5 and P6, and a 322-bp product using primers P1 and P2 ❚Image 2B❚. The expected band (980-bp) of internal control GAPDH mRNA can be easily amplified by RT-PCR from both thyroid and liver tissues with similar intensity for only 25 cycles (Image 2B, lanes 2 and 3, respectively).
Discussion
The incidence and significance of cytoplasmic TTF-1 immunoreactivity in a variety of tumors have been investigated. One study concluded that occasional cytoplasmic staining for TTF-1 (clone 8G7G3/1)in tumors was a nonspecific finding and should be disregarded for diagnostic purposes. 16 However, other recent studies have indicated the usefulness of cytoplasmic immunoreactivity for TTF-1 (clone 8G7G3/1) in the differential diagnosis of primary and metastatic carcinomas of the liver. [12] [13] [14] The cytoplasmic staining of hepatocytes for TTF-1 depends on the type of antibody used, and it varies from 0% (Novocastra, Newcastle upon Tyne, England) to up to 70% positivity (DAKO) (clone 8G7G3/1) in hepatocytes. 17 The antibody we used was from DAKO (clone 8G7G3/1), and our findings were consistent with the findings in the literature. Our cases demonstrated strong and diffuse cytoplasmic staining in cirrhotic and noncirrhotic liver parenchyma. The case with severe acute cellular rejection revealed only weak staining.
The weak staining may result from severe injury of the hepatocytes by rejection. In contrast, there was completely negative staining for TTF-1 in liver mesenchymal cells and inflammatory cells (Image 1).
There are several possible explanations for the cytoplasmic TTF-1 staining (clone 8G7G3/1) in hepatocytes. First, the staining may be due to high level of endogenous biotin present in hepatocytes. The detection kit used for immunohistochemical staining used a refined avidin-biotin technique in which a biotinylated secondary antibody reacts with several peroxidase-conjugated streptavidin molecules, raising the possibility that the cytoplasmic TTF-1 staining could result from a high level of endogenous biotin in hepatocytes. This possibility, however, is excluded because our Western blot analysis that does not use the avidin-biotin technique unequivocally demonstrated intensive staining corresponding to an approximately 160-kd protein (Image 2A).
Second, cytoplasmic TTF-1 staining (clone 8G7G3/1) could come from aberrant expression of TTF-1. As a transcription factor, TTF-1 shows only nuclear staining in thyroid, lung, and ventral forebrain according to a considerable number of previously published studies. [2] [3] [4] [5] After its phosphorylation, the TTF-1 protein moves into cell nuclei and binds to a tissue-specific promoter of downstream target genes such as surfactant proteins and thyroglobulin, activating their expressions. 18 Therefore, any nonnuclear staining of TTF-1 or staining outside the aforementioned specific tissues should be considered an aberrant expression of TTF-1 if the mRNA of TTF-1 is indeed transcribed. However, we were unable to detect TTF-1 mRNA in the liver tissue samples by RT-PCR using a pair of primers (P3 and P4) that span an intron of the TTF-1 gene (Image 2B, lanes 4 and 5). By using the aforementioned pair of primers, we were able to detect true TTF-1 mRNA, rather than DNA contamination, because the latter would show a much larger PCR band if possible (TTF-1 intron, 964 bp; locus, NC_000014). Finally, cytoplasmic TTF-1 staining could result from a cross-reaction of anti-TTF-1 antibody (clone 8G7G3/1). Our Western blot showed an approximately 160-kd protein from liver tissue samples using anti-TTF-1 antibody (clone 8G7G3/1). This protein is apparently much larger than the TTF-1 protein (41 kd) in terms of molecular weight. According to currently released information from National Center for Biotechnology Information, the human TTF-1 gene contains only 2 exons, although a third exon, upstream of the current TTF-1 gene, was reported in 1998, 19 which would be very similar to the gene structure of mouse TTF-1. The larger isoform of mouse TTF-1, which contains all 3 exons, is only 30 amino acids longer than the predominant form (approximately 41 kd), producing an approximately 46-kd protein at most. 6 Therefore, hepatocyte cytoplasmic TTF-1 staining apparently results from a cross-reaction of anti-TTF-1 antibody (clone 8G7G3/1) rather than gene expression of TTF-1.
To reach the preceding conclusion, however, we should exclude the possibility that either of the 2 currently identified human TTF-1 exons may alternately splice with other not yet identified downstream or upstream exons, which produce a high-molecular-weight protein shown on Western blot. Therefore, we designed 2 additional pairs of PCR primers, with P1 and P2 deriving from the coding region of exon 1 and P5 and P6 from the coding region of exon 2 ( Figure 1 ) to test the possibility. We were still not able to detect any mRNA from liver tissue samples (Image 2B, lanes 6 and 7 and 9 and 10), whereas the quality of RNA preparation was verified by an internal control, GAPDH.
Recently, a study showed the binding of TTF-1 (clone 8G7G3/1) and hepatocytes paraffin (Hep Par) 1 to mitochondrial proteins in hepatocytes. 20 In that study, Western blot analysis with cellular proteins extracted from normal human liver demonstrated that Hep Par 1 and TTF-1 bound to a protein band of approximately 150 kd. The authors speculated that different epitopes to Hep Par 1 and TTF-1 share the same protein molecules in hepatocyte mitochondria, and we completely agree. In our Western blot analysis using the same antibody, we showed binding to an approximately 160-kd protein; the discrepancy of estimated molecular weight between our study and the aforementioned study 20 is probably due to a lack of accurate protein markers around that region or to variation from different techniques.
TTF-1 immunoreactivity in hepatocyte cytoplasm is due to an approximately 160-kd protein that reacts with anti-TTF-1 antibody (clone 8G7G3/1). This protein is not from TTF-1 aberrant expression or an alternative slicing product of TTF-1 in hepatocytes. It was not expressed in thyroid or lung tissue samples in our study. The identity of this high-molecularweight protein needs to be further studied.
